Hipertricosis como efecto dermatológico secundario al uso de panitumumab.

Panitumumab is a type of Epidermal Growth Factor Receptor Inhibitor (EGFRI) that belongs to the new antineoplastic therapeutic strategies associated with dermatological adverse effects. Panitumumab has been used for the treatmentof metastatic colon cancer.We report the case of hypertrichosis secondary to panitumumab and we discuss its physiopathology.